In February 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA, through a joint assessment. The two organisations concluded that sufficient information had been accumulated to merit the production of a Joint Report on MDMB-CHMICA as stipulated by Article 5.1 of the Council Decision.